13 Stocks Insiders are Buying Now

Published November 24, 2023 at 10:26 am EST Updated August 31, 2026 at 8:47 pm EDT

In this article, we will take a look at the 13 stocks insiders are buying now.

With the end of 2023 now in sight, many can say with confidence that the much-dreaded recession everyone was talking about will not realize this year. But can this optimism last until the next year? Goldman Sachs in its 2024 outlook report said that it expects the US economy to grow at a modest pace next year but it does not see a recession hitting the economy. Goldman Sachs expects that the S&P 500 index will end 2024 at 4700, which would represent a 12-month gain of 5%

Goldman Sachs also said that at the end of 2024 investors will look back and realize that “all they had to do” was to stay invested (isn’t that the case at the end of every year?). Goldman Sachs also said that the year 2023 has been “defined” by the rise of mega-cap tech stocks, now famously known as the Magnificent Seven. The firm believes the risk reward of these stocks could lose attraction in 2024 because of elevated expectations. Goldman Sachs also looked back at its predictions for 2023 and highlighted where it was right and wrong.

We correctly predicted the aggregate S&P 500 index would show no profit growth. We originally forecast $224 of EPS and 10½ months into the year the market is on track to deliver earnings in line with that number. The equal-weighted S&P 500 index has also posted flat EPS. However, we were wrong because, while the equal-weight index has posted virtually no appreciation YTD, the aggregate index has posted a 19% total return led by stellar returns of a select few mega-cap stocks. The combination of strong realized sales growth, upward estimate revisions, association with the AI theme, and valuation expansion explain the narrow rally. The “Magnificent 7” (AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA) now comprise 29% of S&P 500 market cap and collectively have returned 71% YTD. The remaining 493 stocks in the index have returned just 6%.

Luis Louro / shutterstock.com

Methodology

For this article we used Insider Monkey’s screener for insider trading and picked the biggest insider purchases initiated over the past two months.

Stocks Insiders are Buying Now

13. Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Insider Purchase Date: October 25

Carole Nuechterlein, a director and 10% owner at Aligos Therapeutics, Inc. (NASDAQ:ALGS), in October 2023 bought 7.9 million shares of the biotech company at $0.76 per share. Aligos Therapeutics, Inc. has gained 8.67% over the past one month through November 22. The total value of the transaction was over $6 million.

Earlier this month, Aligos Therapeutics, Inc. filed a prospectus related to the resale of up to an aggregate of 168,725,925 shares of common stock.

Insider Monkey’s database of 910 hedge funds shows that 12 hedge funds tracked by Insider Monkey had stakes in Aligos Therapeutics, Inc. as of the end of the June quarter. At the conclusion of the September quarter the biggest stakeholder of Aligos Therapeutics, Inc. was Oleg Nodelman’s EcoR1 Capital which had a $2.9 million stake.

12. Asana, Inc. (NYSE:ASAN)

Insider Purchase Date: November 1

Asana, Inc. (NYSE:ASAN) ranks 12th in our list of the stocks insiders are buying. Earlier in November Asana, Inc.’s CEO Dustin Moskovitz bought 237,015 shares of the company at $17.50 per share. The CEO of Asana, Inc. has been amassing shares of the company consistently since September this year.

Diamond Hill Capital made the following comment about Asana, Inc. in its Q3 2022 investor letter:

“Work management software company Asana, Inc. (NYSE:ASAN) has, in our view, a relatively undifferentiated and discretionary software product within a software category that will likely be meaningfully smaller than anticipated. Additionally, Asana’s operating losses continue to widen as its revenues have begun decelerating.”

11. CVB Financial Corp. (NASDAQ:CVBF)

Insider Purchase Date: November 1

George A. Borba, a director at CVB Financial Corp. (NASDAQ:CVBF), earlier this month bought 212,000 shares of the California-based banking company on November 1. The total value of this transaction was about $3.4 million.

10. Remitly Global, Inc. (NASDAQ:RELY)

Insider Purchase Date: November 3

Nigel Morris, a board member at financial services company Remitly Global, Inc. (NASDAQ:RELY), bought 250,000 shares of the company earlier this month. The per-share price of the transaction was $19.27. The total transaction value was around $4.82 million.

Earlier this month Remitly Global, Inc. posted Q3 results. GAAP EPS in the quarter came in at -$0.20, missing estimates by $0.04. Revenue in the period jumped about 42.7% year over year to $241.63 million, beating estimates by $2.43 million.

9. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Insider Purchase Date: November 3

Richard Barry, who is a director at Sarepta Therapeutics, Inc. (NASDAQ:SRPT), bought 50,000 shares of the company at $78.81 per share. Sarepta Therapeutics, Inc.’s CEO Douglas Ingram also bought 25,225 shares of the company earlier this month at $79.36 per share.

As of the end of the second quarter of 2023, 53 hedge funds tracked by Insider Monkey had stakes in Sarepta Therapeutics, Inc.. The biggest stakeholder of Sarepta Therapeutics, Inc. was Kurt Von Emster’s VenBio Select Advisor which owns a $530 million stake in the company.

Bronte Capital Amalthea Fund made the following comment about Sarepta Therapeutics, Inc. in its Q3 2023 investor letter:

“The FDA is widely considered to be the world’s foremost regulator of drug products, with a stringent and rigorous process for evaluating new marketing applications. Disagreements between the FDA and regulators in other developed markets (such as the European Medicines Agency or the Australian Therapeutic Goods Administration (TGA)) are rare, and when they do occur, it is usually because the FDA has taken a more critical view of the applicant’s evidence.

For a drug to be approved in the US, it must meet the statutory requirement of “substantial evidence of effectiveness” under the Federal Food, Drug, and Cosmetic Act. There are essentially three ways to meet this requirement. Normally, the FDA expects the sponsor to succeed in two “adequate and well-controlled studies”. Alternatively, the sponsor can rely on success from a single study if the results from that study are “very persuasive”, or if they are combined with some sort of independent confirmatory evidence. For the most part lobbying from the cohort of patients, the “patient voice”, has played a relatively minor role in the FDA’s decision-making process and the agency has been prepared to make tough but rational decisions when the “substantial evidence” standard is clearly not met.

However, this was not the case in 2016 when the FDA famously overruled its own review team and external advisory committee to approve Sarepta Therapeutics, Inc.’s (NASDAQ:SRPT) controversial drug for Duchenne muscular dystrophy (Exondys 51). At the time, Sarepta had completed a single phase 2 trial in just 12 patients which, per the FDA Commissioner (Robert Califf) himself, had “major flaws” in both its design and conduct. Ellis Unger, director of the Office of Drug Evaluation at the FDA, declared that the drug was a “scientifically elegant placebo”, and that patients and their families were taking on unknown risks for likely non-existent benefits…” (Click here to read the full text)

8. Keurig Dr Pepper Inc. (NASDAQ:KDP)

Insider Purchase Date: November 6

Timothy Cofer, Keurig Dr Pepper Inc. (NASDAQ:KDP)’s COO, bought 100,000 shares of the company at a per-share price of $31.17. The total value of this transaction was $3.12 million.

Earlier this month Jefferies started covering Keurig Dr Pepper Inc. stock with a Buy rating. While the firm noted Keurig Dr Pepper Inc.’s at-home coffee business is showing weakness, it is bullish on the stock due to growth in energy, ready-to-drink coffee and tea, and sports drinks categories. Keurig Dr Pepper Inc. set a $39 price target on the stock.

Keurig Dr Pepper Inc. talked about its guidance in Q3 earnings call:

“We are reaffirming our consolidated outlook for 2023 and continue to target constant currency net sales growth of 5% to 6% and adjusted EPS growth of 6% to 7%. Our EPS outlook assumes minimal benefits from nonoperational items in 2023, implying double-digit EPS growth on an underlying basis. Our guidance for below-the-line items is consistent with last quarter. For the year, we continue to expect interest expense in a $470 million to $475 million range, effective tax rate of 22% and approximately $1.41 billion diluted weighted average shares outstanding. We expect a strong end to the year in quarter four with similar top-line dynamics in quarter three and even a stronger gross margin expansion. At the same time, we will be lapping approximately $67 million of nonoperational gains in last year’s fourth quarter, primarily concentrated in the U.S. Coffee segment, which creates a challenging comparison.

Blending these factors together, we expect Q4 adjusted EPS of approximately $0.54 or 8% year-over-year growth. On an underlying basis, this represents strong double-digit EPS growth.”

Read the full earnings call transcript here.

7. Exxon Mobil Corp (NYSE:XOM)

Insider Purchase Date: November 6

Famous activist investor Jeff Ubben, who is also a board member at Exxon Mobil Corp (NYSE:XOM), amassed 250,000 shares of the oil giant earlier this month. The average per-share price of the transaction was $105.97.

Out of the 910 hedge funds tracked by Insider Monkey, 71 hedge funds reported having stakes in Exxon Mobil Corp. The biggest stakeholder of Exxon Mobil Corp was Jean-Marie Eveillard’s First Eagle Investment Management which had a $1.4 billion stake in Exxon Mobil Corp.

6. Enstar Group Limited (NASDAQ:ESGR)

Insider Purchase Date: November 7

Insurance company Enstar Group Limited (NASDAQ:ESGR) is one of the stocks insiders are purchasing. Enstar Group Limited’s CEO Dominic Francis Michael Silvester bought 45,000 shares of the company at a per-share price of $227.18.

As of the end of the second quarter of 2023, 10 hedge funds out of the 910 funds tracked by Insider Monkey reported owning stakes in Enstar Group Limited. As of the end of the September quarter, the biggest stakeholder of Enstar Group Limited was Harry Gail’s Harspring Capital Management which owns a $42 million stake in the company.

Diamond Hill Capital made the following comment about Enstar Group Limited in its Q4 2022 investor letter:

“Other top contributors included Enstar Group Limited (NASDAQ:ESGR), ESAB Corp and Taseko Mines. Shares of runoff consolidator Enstar bounced back from a tough Q3. Enstar buys other companies’ non-core business lines and efficiently settles claims until the liabilities are exhausted. It has a proven ability to compound value over time and create value across cycles, and we believe it can continue to do so.”

5. Block, Inc. (NYSE:SQ)

Insider Purchase Date: November 8

Block, Inc. (NYSE:SQ) ranks 5th in our list of the stocks insiders are buying now. Both Roelof, a director at Block, Inc., bought a whopping 23,433 shares of the company at $50.97 per share earlier this month. In another transaction, the director bought 15,262 shares of Block, Inc. at a per-share price of $50.99.

As of the end of the second quarter of 2023, 66 hedge funds tracked by Insider Monkey had stakes in Block, Inc.. The biggest stakeholder of Block, Inc. as of the end of the September was Andreas Halvorsen’s Viking Global which had a $545 million stake in the company.

Here is what Baron FinTech Fund has to say about Block, Inc. in its Q3 2023 investor letter:

“Block, Inc. provides point-of-sale technology to small businesses and operates the Cash App ecosystem of financial services for individuals. Shares fell due to a confluence of factors, including slowing growth, a brief system outage, and the departure of a key executive who ran the Square business segment. Ongoing investor concerns over consumer spending and a recession did not help sentiment. Nevertheless, Block reported strong quarterly results with 27% gross profit growth and adjusted EBITDA more than doubling. We believe Block’s businesses are resilient, and greater management focus on cost discipline should drive further margin expansion. We continue to own the stock due to Block’s long runway for growth, durable competitive advantages, and track record of innovation.”

4. Janux Therapeutics, Inc. (NASDAQ:JANX)

Insider Purchase Date: November 13

A lot of insider buying activity has been taking place at Janux Therapeutics, Inc. (NASDAQ:JANX), a California-based biopharma company. Earlier in November Jay Lichter, a director and 10% owner at the company, bought a whopping $4.9 million worth of company shares at $5.87 a piece. Tighe Reardon, Janux Therapeutics, Inc.’s acting CFO, also amassed 849,854 shares of the company at a per-share price of $5.87.

3. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Insider Purchase Date: November 13

Clinical stage biopharma company Madrigal Pharmaceuticals, Inc. ranks 3rd in our list of the stocks insiders are buying now. Baker Bros. Advisors LP, which has a director status on Madrigal Pharmaceuticals, Inc.’s board, bought 107,499 shares of the company earlier this month at $146.99 per share. Over the past one month the stock has gained about 50%.

Earlier this month Madrigal Pharmaceuticals, Inc. posted Q3 results. GAAP EPS in the quarter came in at -$5.34 missing estimates by $0.38.

2. Howard Hughes Holdings Inc. (NYSE:HHH)

Insider Purchase Date: November 15

Pershing Square Capital Management, L.P., who is both a director and a 10% owner at Howard Hughes Holdings Inc. (NYSE:HHH), earlier this month bought 201,600 shares of the company at an average price of $74.34 per share. In another insider purchase initiated on November 7, Pershing Square Capital bought 190,248 shares of Howard Hughes Holdings Inc. at $72.24 per share.

Earlier this month Howard Hughes Holdings Inc. posted third quarter results. GAAP EPS in the third quarter came in at -$10.97. Revenue fell about 58% year over year to $268.7 million, beating estimates by $37.81 million.

Pershing Square Holdings made the following comment about Howard Hughes Holdings Inc. in its first half 2023 investor letter:

“Howard Hughes Holdings Inc. (NYSE:HHH)’s high-quality collection of well-located master planned communities (“MPC”) delivered resilient performance in the first half of 2023 led by a strong recovery in the housing market and robust leasing momentum in the company’s income producing operating assets.

Mortgage interest rates have stabilized this year after rapidly rising in 2022. The supply of home resale inventory remains constrained as homeowners are reluctant to sell their existing homes and incur more expensive mortgages. As a result, there has been a resurgence in demand for newly built homes. Amidst that backdrop, the relative affordability of HHH’s MPCs, which are located in low cost-of-living and low-tax states like Texas and Nevada, remains highly appealing to prospective homebuyers. New home sales in HHH’s MPCs increased 11% year-over-year in the first half of 2023, reflecting strong demand for future land sales and causing the company to raise its guidance for full-year 2023 MPC land sale profits by 20%.

In HHH’s income-producing operating assets, net operating income (“NOI”) grew 6% on a same-store basis during the first half of the year driven by improving leasing velocity and strong rental rate growth. The company’s office portfolio is benefiting from a “flight to quality” as companies and their employees are drawn to the desirability of HHH’s walkable and amenity-rich MPCs. Likewise, in the company’s condominium development at Ward Village, Hawaii, HHH continues to experience durable sales momentum with its latest condo tower already 83% pre-sold within nine months of its launch. In the most recent quarter, the company contracted to sell 43 units, representing an impressive 27% of available unit inventory. At its Seaport development in New York City, the company is focused on driving operational improvements at the recently opened Tin Building food hall, which continues to generate operating losses in its first full year of operations.…” (Click here to read the full text)

1. Groupon, Inc. (NASDAQ:GRPN)

Insider Purchase Date: November 16

Groupon, Inc. (NASDAQ:GRPN)’s interim CEO Dušan Šenkypl bought 323,344 shares of the company earlier this month at an average per-share price of $9.49. Earlier this month the stock plummeted after Groupon, Inc.’s Q3 revenue figures missed estimates. Groupon, Inc. also said it sees 2024 sales flat to -5%.

You can also take a peek at 25 Worst States for Human Trafficking in America and 20 Most Common Places to Get Kidnapped.